# Development of a Novel Therapeutic for Melioidosis

> **NIH NIH N01** · AN2 THERAPEUTICS, INC. · 2024 · $3,821,365

## Abstract

To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment.

## Key facts

- **NIH application ID:** 11090309
- **Project number:** 75N93022C00059-P00004-9999-1
- **Recipient organization:** AN2 THERAPEUTICS, INC.
- **Principal Investigator:** M.R.K. (DICKON) ALLEY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,821,365
- **Award type:** —
- **Project period:** 2022-09-20 → 2026-08-13

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11090309

## Citation

> US National Institutes of Health, RePORTER application 11090309, Development of a Novel Therapeutic for Melioidosis (75N93022C00059-P00004-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11090309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*